Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more
Tharimmune Inc. (THAR) - Total Liabilities
Latest total liabilities as of September 2025: $1.54 Million USD
Based on the latest financial reports, Tharimmune Inc. (THAR) has total liabilities worth $1.54 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tharimmune Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Tharimmune Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tharimmune Inc. Competitors by Total Liabilities
The table below lists competitors of Tharimmune Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Sanfer Electric Co. Ltd
SHG:605336
|
China | CN¥158.88 Million |
|
Golconda Gold Ltd.
V:GG
|
Canada | CA$14.61 Million |
|
63 moons technologies limited
NSE:63MOONS
|
India | ₹2.89 Billion |
|
Tudor Gold Corp
PINK:TDRRF
|
USA | $16.81 Million |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
China | CN¥109.88 Million |
|
SNP Schneider-Neureither & Partner SE
XETRA:SHF
|
Germany | €178.52 Million |
|
Hume Industries Berhad
KLSE:5000
|
Malaysia | RM424.37 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Tharimmune Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tharimmune Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tharimmune Inc. (2019–2024)
The table below shows the annual total liabilities of Tharimmune Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.41 Million | +33.00% |
| 2023-12-31 | $1.82 Million | +58.52% |
| 2022-12-31 | $1.14 Million | -78.42% |
| 2021-12-31 | $5.31 Million | +32.26% |
| 2020-12-31 | $4.01 Million | +141.26% |
| 2019-12-31 | $1.66 Million | -- |